Applicant:

Gholam-Reza Zadno-Azizi, et al.

Serial No.:

10/081,569

Filed:

February 21, 2002

For:

BODY FLUID FLOW CONTROL

DEVICE

Art Unit:

3738

Examiner:

Unassigned

RECEIVED

APR 23 2003

FERHNOLUGY GENTER 3700

RECEIVED

APR 2 4 2003

TECHNOLOGY CENTER R3700

TRANSMITTAL LETTER

US Patent and Trademark Office PO Box 2327 Arlington, VA 22202

`Sir:

Transmitted herewith are a Supplemental Information Disclosure Statement, cited references and a PTO-Form 1449 (3 page) for filing in connection with the above-identified application. Because this Supplemental Information Disclosure Statement is filed after receipt of a First Office Action on the merits for the above-captioned application but before either a Final Office Action or Notice of Allowance in the above-referenced application, a fee for filing this statement is included herewith. However, should said fee be either missing or incorrect, the Commissioner is authorized to charge deposit account No. 50-1213, for the appropriate fee as stated below:

[X] The Commissioner is hereby authorized to charge any fees that may be due under 37 C.F.R. §§1.16-1.17 in connection with this paper or with this application during its entire pendency to Deposit Account No. 05-1213. A duplicate of this sheet is enclosed.

Respectfully submitted,

HELLER EHRMAN WHITE & McAULIFFE LLP

By:

Fred C. Hernandez

Registration No. 41,832

Dated: April 22, 2003

Attorney Docket No. 38349-0102D

Address all correspondence to:

11/18/2004 SDRYCE

22220021 19981569

Stephanie L. Seidman

Fred C. Hernandez
HELLER EHRMAN WHITE & McAULIFFE LLP

4350 La Jolla Village Drive, Suite 700

San Diego, CA 92122-1246

61 F0:1866 Facsimile: (858) 587-5360 183.62 CP

Telephone: (858) 450-8400

SD 608991 v1 (38349.0102)

Applicant:

Gholam-Reza Zadno-Azizi, et al.

Serial No.:

10/081,569

Filed:

February 21, 2002

For:

BODY FLUID FLOW CONTROL

DEVICE

Art Unit:

3738

Examiner:

Unassigned

TRANSMITTAL LETTER

US Patent and Trademark Office PO Box 2327 Arlington, VA 22202

Sir:

Transmitted herewith are a Supplemental Information Disclosure Statement, cited references and a PTO-Form 1449 (3 page) for filing in connection with the above-identified application. Because this Supplemental Information Disclosure Statement is filed after receipt of a First Office Action on the merits for the above-captioned application but before either a Final Office Action or Notice of Allowance in the above-referenced application, a fee for filing this statement is included herewith. However, should said fee be either missing or incorrect, the Commissioner is authorized to charge deposit account No. 50-1213, for the appropriate fee as stated below:

[X] The Commissioner is hereby authorized to charge any fees that may be due under 37 C.F.R. §§1.16-1.17 in connection with this paper or with this application during its entire pendency to Deposit Account No. 05-1213. A duplicate of this sheet is enclosed.

Respectfully submitted,

HELLER EHRMAN WHITE & McAULIFFE LLP

By:

Fred C. Hernandez Registration No. 41,832

Dated: April 22, 2003

Attorney Docket No. 38349-0102D Address all correspondence to:

Stephanie L. Seidman Fred C. Hernandez

HELLER EHRMAN WHITE & McAULIFFE LLP

4350 La Jolla Village Drive, Suite 700

San Diego, CA 92122-1246

Telephone: (858) 450-8400

Facsimile: (858) 587-5360

Applicant:

Gholam-Reza Zadno-Azizi, et al.

Serial No.:

10/081,569

Filed:

February 21, 2002

For:

BODY FLUID FLOW CONTROL

DEVICE

Art Unit:

3738

Examiner:

Unassigned

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN ACCORDANCE WITH 37 C.F.R. §§ 1.97-1.98

PO Box 2327 Arlington, VA 22202

Sir:

Since this Supplemental Information Disclosure Statement is filed after receipt of a first Office Action on the merits for the above-captioned application, the filing fee of \$180.00 is enclosed. If no proper payment is enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal, or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-1213.

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Supplemental Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§ 1.97-1.98 Forms PTO-1449 (3 pages) and copies of the cited documents are provided herewith in connection with the above-captioned application.

The documents listed on the Form PTO-1449 and supplied herewith are in the

USSN 10/081,569 ZADNO-AZIZI *et al.* SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

English language except items AU & AV which are in the Russian language. Items AU (Russian patent 2140211) & AV (Soviet Union patent 852321) are provided with an English language equivalent (items AX & AY respectively). Hence, in accordance with the requirements of 37 C.F.R. § 1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. § 1.56(b) exists.

Applicant respectfully requests that the Examiner review the foregoing references and make them of record in the file history of the above-captioned application.

Respectfully submitted,

HELLER EHRMAN WHITE & McAULIFFE LLP

By:

Fred C. Hernandez

Registration No. 41,832

Dated: April 22, 2003

Attorney Docket No. 38349-0102D Address all correspondence to:

Stephanie L. Seidman Fred C. Hernandez HELLER EHRMAN WHITE & McAULIFFE LLP 4350 La Jolla Village Drive, Suite 700

San Diego, CA 92122-1246 Telephone: (858) 450-8400 Facsimile: (858) 587-5360

INFORMATION DISCLOSURE STATEMENT

UNDER 37 CFR §1.56, §1.97, and §1.98

PTO-1449 FORM

ATTORNEY DOCKET NO.: 38349-0102D

SERIAL NO.: 10/081,569

APPLICANTS:

Zadno-Azizi et al.

FILING DATE:

GROUP ART UNIT: 3738

Sheet 1 of 3

February 21, 2002

		U.S. PA	TENT DOCU	MENTS
†EX'R				

1 =>0=	I		T			
† EX'R INITIAL	REF.#	PATENT NUMBER	DATE	NAME	U.S. CLASS/ SUBCLASS	FILING DATE (If appropriate)
 	Α	2003/0050648 (A1)	03/13/03	Alferness et al.	606/108	09/11/01
	В	2003/0018344 (A1)	01/23/03	Kaji et al.	606/130	07/19/02
·	С	2003/0018327 (A1)	01/23/03	Truckai <i>et al.</i>	606/32	07/18/02
	D	2002/0138135 (A1)	09/26/02	Duerig et al.	623/1.24	03/21/01
	Е	2002/0007831(A1)	1/24/02	Davenport et al.	128/200.24	7/18/01
	F	2,981,254	04/25/61	Vanderbilt	128/350	11/12/57
_	G	3,657,744	04/25/72	Ersek	128/334	05/08/70
11.	Н	3,788,327	01/29/74	Donowitz et al.	128/350	03/30/71
	1	3,874,388	04/01/75	King et al.	128/334	02/12/73
	J	4,014,318	03/29/77	Dockum et al	128/1	05/22/75
	К	4,212,463	07/15/80	Repinski et al.	273/418	02/17/78
	L	4,302,854	12/01/81	Runge	3/1.7	06/04/80
	М	4,846,836	07/11/89	Reich	623/11	10/03/88
	N	4,852,568	08/01/89	Kensey	128/325	12/28/87
	0	4,968,294	11/06/90	Salama	600/30	02/09/89
	Р	5,061,274	10/29/91	Kensey	606/213	12/04/89
	Q	5,161,524	11-92	Evans	128/203.15	
	R	5,306,234	04/26/94	Johnson	604/49	03/23/93
	S	5,352,240	10/04/94	Ross	623/2	05/31/89
	T	5,366,478	11/22/94	Brinkerhoff et al.	660/213	07/27/93
	U	5,409,019	04/25/95	Wilk	128/898	11/03/93
	V	5,413,599	05/09/95	Imachi et al.	623/2	12/13/93
	W	5,645,565	07/08/97	Rudd et al.	606/213	06/13/93

EXAMINER'S SIGNATURE		
LAAMINER S SIGNATURE	DATE	- 1
	CONSIDER	ED

[†] EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. *Include copy of this form in next communication to applicant*.

^{*} If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d). #608892v1 P1449-38349-0102D

INFORMATION DISCLOSURE STATEMENT

UNDER 37 CFR §1.56, §1.97, and §1.98

PTO-1449 FORM

Sheet 2 of 3

ATTORNEY DOCKET NO.: 38349-0102D

SERIAL NO.: 10/081,569

APPLICANTS:

Zadno-Azizi et al.

FILING DATE:

February 21, 2002

GROUP ART UNIT: 3738

		U.S. P	ATENT DOCUMENTS		
Х	5,697,968	12/16/97	Rogers et al.	623/1	08/10/95
Y	5,800,339	09/01/98	Salama	600/29	05/02/97
Z	5,851,232	12/22/98	Lois	623/1	3/13/97
AA	5,855,597	01/5/99	Jayaraman	623/1	5/7/97
AB	5,944,738	08/31/99	Amplatz et al.	606/213	02/06/98
AC	5,947,997	09/07/99	Pavcnik et al.	606/213	06/30/97
AD	5,976,174	11/02/99	Ruiz	606/213	12/15/97
AE	6,068,638	05/30/00	Makower	606/159	10/27/98
AF	6,077,291	06/20/00	Das	606/213	11/26/96
AG	6,135,729	10/24/00	Aber	417/420	07/09/99
AH `	6,245,102 B1	06/12/01	Jayaraman	623/1.15	07/03/99
Al	6,493,589 (B1)	12/10/02	Medhkour et al.	607/99	
AJ	6,510,846 (B1)	01/28/03	O'Rourke	128/200.21	08/10/00
AK	6,527,761 B1	3/4/03	Soltesz et al.	604/516	10/26/00 10/27/00

	FOREIGN PATENT DOCUMENTS							
† EX'R INITIAL	REF.#	Patent Number	Date	Country	TRANSLATION (YES/NO)			
	AL	00/78407 (A1)	12/28/00	PCT	(, = , , ,)			
	AM	01/13908 (A2)	03/01/01	PCT				
	AN	01/54685 (A1)	08/02/01	PCT				
	AO	01/95786 (A2)	12/20/01	PCT				
	AP	02/05884 (A2)	1/24/02	PCT				
	AQ	02/34322 (A2)	5/2/02	PCT				

EXAMINER'S SIGNATURE	
	DATE
	CONSIDERED

[†] EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. *Include copy of this form in next communication to applicant*.

^{*} If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d). #608892v1 P1449-38349-0102D

INFORMATION DISCLOSURE STATEMENT

UNDER 37 CFR §1.56, §1.97, and §1.98

PTO-1449 FORM

Sheet 3 of 3

	ATTORNEY DOCKET NO.: 38349-0102D	SERIAL NO.: 10/081,569
	APPLICANTS:	
	Zadno-Azizi et al.	
l	FILING DATE:	GROUD ART

February 21, 2002

GROUP ART UNIT: 3738

		FOREIGN PA	TENT DOCUMENTS	
AF	R 02/47575 (A2)	06/20/02	PCT	T
AS	02/094087 (A1)	11/28/02	PCT	
AT	03/022124 (A2)	03/20/03	PCT	
AL	2140211	10/27/99	RU	×
AV	852321	07/08/81	SU	X

x English Language Derwent is enclosed.

	OTHER DOCUMENTS						
† EX'R INITIAL	REF.#	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)					
	AW	Al Jishi et al., "Selective Bronchial Occlusion for Treatment of Bullous Interstitial Emphysema and Bronchopleural Fistula." <i>J. of Pediatric Surgery</i> , 29:12, 1994: 1545-1547.					
	AX	Derwent citing Russian Patent No. RU 2140211, published 10/27/99, for: "Method of surgical treatment of patients with pathology of respiratory organs complicated with pulmonary homographs and "					
	AY	pleural disease in children - by pneumo-abcessoromy simultaneous with poelusion of effects at the					
		Means of an Intratracheal Ball Valve." <i>J. Exp Med</i> 30:1919: 75-88					
	BA Į	Lewis et al. "Pulmonary Interstitial Emphysema: Selective Broncial Occlusion with a Swan-Ganz Catheter." Archives of Disease in Childhood, 63:1988, 313-315					
	BB	Mathew et al. "Selective bronchial obstruction for treatment of bullous interstitial emphysema." J. of Ped. 96:1980, 475-477					
	ВС	Okada et al. "Emergent Bronchofiberoptic Bronchial Occlusion for Intractable Pneumothorax with Sever Emphysema." <i>The Jap. J. of Thor. And Cardio. Sur.</i> 46:11, 1998 1078-1081					
	ן עם	Puhakka et al. "Acute Bronchial Obstruction: An Experimental Rabbit Model Study." Int. J. of Pediatric Otorhinolaryngology. 18:1989, 107-118.					
	RE	Snider et al., <u>The Definition of Emphysema</u> : Report of the National Heart Lung and Blood Institute, Division of Lung Diseases Workshop, <i>Am. Rev. Respir. Dis.</i> , <u>132</u> :182, 1985					

EXAMINER'S SIGNATURE	
	DATE CONSIDERED

[†] EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. *Include copy of this form in next communication to applicant.*

^{*} If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d). #608892v1 P1449-38349-0102D

INFORMATION DISCLOSURE STATEMENT

UNDER 37 CFR §1.56, §1.97, and §1.98

PTO-1449 FORM

Sheet 1 of 3

ATTORNEY DOCKET NO.: 38349-0102D

SERIAL NO.: 10/081,569

APPLICANTS:

Zadno-Azizi et al.

FILING DATE:

February 21, 2002

GROUP ART UNIT: 3738

	• •		U.S. P	ATENT DOCUMENTS		£ -1 - 2
			*			
† EX'R INITIAL	REF.#	PATENT NUMBER	DATE	NAME	U.S. CLASS/ SUBCLASS	FILING DATE (If appropriate)
	Α	2003/0050648 (A1)	03/13/03	Alferness et al.	606/108	09/11/01
	В	2003/0018344 (A1)	01/23/03	Kaji et al.	606/130	07/19/02
	С	2003/0018327 (A1)	01/23/03	Truckai et al.	606/32	07/18/02
	D	2002/0138135 (A1)	09/26/02	Duerig et al.	623/1.24	03/21/01
-	Е	2002/0007831(A1)	1/24/02	Davenport et al.	128/200.24	7/18/01
1	F	2,981,254	04/25/61	Vanderbilt	128/350	11/12/57
	G	3,657,744	04/25/72	Ersek	128/334	05/08/70
	Н	3,788,327	01/29/74	Donowitz et al.	128/350	03/30/71
	i	3,874,388	04/01/75	King et al.	128/334	02/12/73
	J	4,014,318	03/29/77	Dockum et al	128/1	05/22/75
	K	4,212,463	07/15/80	Repinski et al.	273/418	02/17/78
	L	4,302,854	12/01/81	Runge	3/1.7	06/04/80
	М	4,846,836	07/11/89	Reich	623/11	10/03/88
	N	4,852,568	08/01/89	Kensey	128/325	12/28/87
	0	4,968,294	11/06/90	Salama	600/30	02/09/89
	Р	5,061,274	10/29/91	Kensey	606/213	12/04/89
	Q	5,161,524	11-92	Evans	128/203.15	
	R	5,306,234	04/26/94	Johnson	604/49	03/23/93
	S	5,352,240	10/04/94	Ross	623/2	05/31/89
	Т	5,366,478	11/22/94	Brinkerhoff et al.	660/213	07/27/93
	U	5,409,019	04/25/95	Wilk	128/898	11/03/93
	V	5,413,599	05/09/95	Imachi et al.	623/2	12/13/93
-	W	5,645,565	07/08/97	Rudd et al.	606/213	06/13/93

	· · · · · · · · · · · · · · · · · · ·	 	 4	
EXAMINER'S SIGNATURE				DATE
				CONSIDERED

[†] EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. *Include copy of this form in next communication to applicant.*

^{*} If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d). #608892v1 P1449-38349-0102D

INFORMATION DISCLOSURE STATEMENT

UNDER 37 CFR §1.56, §1.97, and §1.98

PTO-1449 FORM

Sheet 2 of 3

ATTORNEY DOCKET	NO.:
38349-0102D	

SERIAL NO.: 10/081,569

APPLICANTS:

Zadno-Azizi et al.

February 21, 2002

FILING DATE:

GROUP ART UNIT: 3738

• • •	* 1 -	* * * * * *	U.S. P.	ATENT DOCUMENTS	*		
	Х	5,697,968	12/16/97	Rogers et al.	623/1	08/10/95	
	Y	5,800,339	09/01/98	Salama	600/29	05/02/97	
,	Z	5,851,232	12/22/98	Lois	623/1	3/13/97	
	AA	5,855,597	01/5/99	Jayaraman	623/1	5/7/97	
	AB	5,944,738	08/31/99	Amplatz et al.	606/213	02/06/98	
	AC	5,947,997	09/07/99	Pavcnik et al.	606/213	06/30/97	
	AD	5,976,174	11/02/99	Ruiz	606/213	12/15/97	
6	AE	6,068,638	05/30/00	Makower	606/159	10/27/98	
	AF	6,077,291	06/20/00	Das	606/213	11/26/96	
* .	AG	6,135,729	10/24/00	Aber	417/420	07/09/99	
-	AH	6,245,102 B1	06/12/01	Jayaraman	623/1.15	07/21/99	
	Al ,	6,493,589 (B1)	12/10/02	Medhkour et al.	607/99	08/10/00	
	AJ	6,510,846 (B1)	01/28/03	O'Rourke	128/200.21	10/26/00	
	AK	6,527,761 B1	3/4/03	Soltesz et al.	604/516	10/27/00	

	FOREIGN PATENT DOCUMENTS										
† EX'R INITIAL	REF.#	Patent Number	Date		Country	."	TRANSLATION (YES/NO)				
	AL	00/78407 (A1)	12/28/00		PCT						
	AM	01/13908 (A2)	03/01/01		PCT						
	AN	01/54685 (A1)	08/02/01	9.0	PCT						
	AO .	01/95786 (A2)	12/20/01		PCT	12					
	AP	02/05884 (A2)	1/24/02		PCT						
	AQ	02/34322 (A2)	5/2/02		PCT						

EXAMINER'S SIGNATURE DATE CONSIDERED

[†] EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. *Include copy of this form in next communication to applicant.*

^{*} If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).

INFORMATION DISCLOSURE STATEMENT

UNDER 37 CFR §1.56, §1.97, and §1.98

PTO-1449 FORM

ATTORNEY DOCKET NO.: 38349-0102D

SERIAL NO.: 10/081,569

APPLICANTS:

Zadno-Azizi et al.

FILING DATE:

GROUP ART UNIT: 3738

Sheet 2 of 3

February 21, 2002

	*	U.S. P	ATENT DOCUMENTS		: :
Х	5,697,968	12/16/97	Rogers et al.	623/1	08/10/95
Y	5,800,339	09/01/98	Salama	600/29	05/02/97
Z	5,851,232	12/22/98	Lois	623/1	3/13/97
AA	5,855,597	01/5/99	Jayaraman	623/1	5/7/97
AB	5,944,738	08/31/99	Amplatz et al.	606/213	02/06/98
AC	5,947,997	09/07/99	Pavcnik et al.	606/213	06/30/97
AD	5,976,174	11/02/99	Ruiz	606/213	12/15/97
AE	6,068,638	05/30/00	Makower	606/159	10/27/98
AF	6,077,291	06/20/00	Das	606/213	11/26/96
AG	6,135,729	10/24/00	Aber	417/420	07/09/99
AH	6,245,102 B1	06/12/01	Jayaraman	623/1.15	07/21/99
Al	6,493,589 (B1)	12/10/02	Medhkour et al.	607/99	08/10/00
AJ	6,510,846 (B1)	01/28/03	O'Rourke	128/200.21	10/26/00
AK	6,527,761 B1	3/4/03	Soltesz et al.	604/516	10/27/00

	FOREIGN PATENT DOCUMENTS									
† EX'R INITIAL	REF.#	Patent Number	Date	Country	TRANSLATION (YES/NO)					
	AL	00/78407 (A1)	12/28/00	PCT						
÷ų	AM	01/13908 (A2)	03/01/01	PCT						
	AN	01/54685 (A1)	08/02/01	PCT	. ·					
	AO	01/95786 (A2)	12/20/01	PCT	· ·					
1	AP	02/05884 (A2)	1/24/02	PCT						
	AQ	02/34322 (A2)	5/2/02	PCT						

EXAMINER'S SIGNATURE

DATE
CONSIDERED

[†] EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. *Include copy of this form in next communication to applicant*.

^{*} If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d). #608892v1 P1449-38349-0102D

INFORMATION DISCLOSURE STATEMENT

UNDER 37 CFR §1.56, §1.97, and §1.98

PTO-1449 FORM

ATTORNEY DOCKET NO.: 38349-0102D

SERIAL NO.: 10/081,569

APPLICANTS:

Zadno-Azizi et al.

February 21, 2002

FILING DATE:

GROUP ART UNIT: 3738

Sheet 3 of 3

			FOREIGN	FOREIGN PATENT DOCUMENTS							
18.	AR	02/47575 (A2)	06/20/02		PCT					Υ.	
*	AS	02/094087 (A1)	11/28/02		PCT			-			
	AT	03/022124 (A2)	03/20/03	,	PCT						
	AU	2140211	10/27/99		RU	=	- 10 °		10	Х	
	AV	852321	07/08/81		SU					X	

x English Language Derwent is enclosed.

*		OTHER DOCUMENTS
† EX'R INITIAL	REF.#	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)
*	AW	Al Jishi et al., "Selective Bronchial Occlusion for Treatment of Bullous Interstitial Emphysema and Bronchopleural Fistula." <i>J. of Pediatric Surgery</i> , 29:12, 1994: 1545-1547.
	AX	Derwent citing Russian Patent No. RU 2140211, published 10/27/99, for: "Method of surgical treatment of patients with pathology of respiratory organs complicated with pulmonary hemorrhages"
*	AY	Derwent citing Soviet Union Patent No. SU 852-321, published 07/08/81, for: "Treatment for acute pulmonary and pleural disease in children - by pneumo-abcessotomy simultaneous with occlusion of affected lung part"
*	AZ	Harris et al., "The Experimental Production in Dogs of Emphysema with Associated Asthmatic Syndrome by Means of an Intratracheal Ball Valve." <i>J. Exp Med</i> 30:1919; 75-88
	ВА	Lewis et al. "Pulmonary Interstitial Emphysema: Selective Broncial Occlusion with a Swan-Ganz Catheter." Archives of Disease in Childhood, 63:1988, 313-315
	BB	Mathew et al. "Selective bronchial obstruction for treatment of bullous interstitial emphysema." <i>J. of Ped.</i> 96:1980, 475-477
	ВС	Okada et al. "Emergent Bronchofiberoptic Bronchial Occlusion for Intractable Pneumothorax with Sever Emphysema." The Jap. J. of Thor. And Cardio. Sur. 46:11, 1998 1078-1081
-	BD	Puhakka et al. "Acute Bronchial Obstruction: An Experimental Rabbit Model Study." Int. J. of Pediatric Otorhinolaryngology. 18:1989, 107-118.
	BE	Snider et al., <u>The Definition of Emphysema</u> : Report of the National Heart Lung and Blood Institute, Division of Lung Diseases Workshop, <i>Am. Rev. Respir. Dis.</i> , <u>132</u> :182, 1985

	EXAMINER'S SIGNATURE				9	-	 · · · · · ·	DATE
i		, ,		· •	. (7)			CONSIDERED
					Ξ			

[†] EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. *Include copy of this form in next communication to applicant.*

^{*} If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d). #608892v1 P1449-38349-0102D